Clinical Trial News - BioPharma Dive
WEB3 days ago · Struggling 2Seventy scraps a key cancer study. The biotech expects that stopping enrollment for KarMMa-9, a trial evaluating early use of the multiple myeloma cell therapy Abecma, should save it $80 million in the near term. By Jacob Bell • Sept. 25, 2024. Explore the Trendline .
10 clinical trials to watch in the first half of 2024
WEBJan 2, 2024 · Moderna and Pfizer both reported promising results in early testing last fall and have moved on to late-stage studies. Moderna appears positioned to get to the finish line first. Results from its Phase 3 trial could be coming in the first half of this year, according to a federal database. — Delilah Alvarado.
Roche, following setbacks, turns to its next Alzheimer’s drug
WEBMar 11, 2024 · Like several of its peers, Roche is still plugging away at Alzheimer’s research despite multiple setbacks. The clinical disappointments of its drugs gantenerumab and crenezumab were part of a run of Alzheimer’s study failures that led many researchers to question whether removing amyloid plaques would actually help patients with the …
10 clinical trials to watch in the first half of 2023
WEBJan 3, 2023 · Sometime in the first half of this year, a key clinical trial of around 250 people should help answer whether RVT-3101 can effectively treat moderate-to-severe ulcerative colitis. Though cross-trial comparisons can be difficult, the results could also give investors a better sense of how Pfizer and Roivant’s drug stacks up.
Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Clinical Trial News | BioPharma Dive
WEBMay 29, 2024 · Systems thinking: A new paradigm for clinical trial design and operations Applying a systems thinking framework to clinical trial design prompts purposeful and productive collaboration among stakeholders. By John Doyle, Dr.P.H., President of Consulting at Fortrea • April 29, 2024
10 clinical trials to watch in the first half of 2022
WEBJan 3, 2022 · Faced with conflicting clinical trial data, the FDA chose to clear Aduhelm based on how it is thought to work, elevating a long-debated and unproven disease hypothesis in the process. Over the course of 2022, study results from Roche and Eisai could offer supporting evidence for Aduhelm, its developer Biogen and the FDA, or …
10 clinical trials to watch in the second half of 2023
WEBJun 28, 2023 · 10 clinical trials to watch in the second half of 2023. A Duchenne gene therapy faces a crucial test, while highly anticipated study results lay ahead in lung cancer, obesity and heart disease. The next six months will be full of dramatic moments for the biotechnology industry. The Food and Drug Administration will either be validated or ...
CRO disputes Acelyrin’s implication of trial misconduct
WEBNov 30, 2023 · The back-and-forth between Acelyrin and Fortrea marks the second high-profile CRO dispute this year. In February, Pfizer and Valneva removed about half of the patients from a large Phase 3 trial of an experimental Lyme disease vaccine because of what they called standard violations. The clinical trial contractor, Care Access, later said …
10 clinical trials to watch in the second half of 2022
WEBJul 5, 2022 · The second half of the year could bring similarly important results from clinical trials testing drugs for Alzheimer’s disease, cancer and vision loss. Positive data, if it comes, might give biotech a needed boost. Here are 10 trials to watch: Companies: Eisai, Biogen. Disease: Alzheimer's. Treatment type: